This site is intended for healthcare professionals

Zimhi resubmitted NDA is accepted by the FDA for the treatment of opioid overdose.-Adamis Pharmaceuticals

Read time: 1 mins
Last updated:10th Jun 2021
Published:11th Jun 2021
Adamis Pharmaceuticals Corporation announced that the FDA has accepted for review the Company’s resubmitted New Drug Application (NDA) for Zimhi, which is its higher naloxone injection product candidate for the treatment of opioid overdose.
Condition: Opioid Dependence/Overdose
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest